View Archive

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Supporter

This activity is funded entirely by Physicians’ Education Resource®, LLC.

9th Annual International Symposium on Ovarian Cancer and Gynecologic Malignancies®

9th Annual International Symposium on Ovarian Cancer and Gynecologic Malignancies®

Click here to download brochure


The 9th Annual International Symposium on Ovarian Cancer and Gynecologic Malignancies® is a one-day educational and scientific meeting that will focus on key clinical topics in the management of ovarian cancer as well as endometrial, uterine, and cervical malignancies.

Join this leading faculty of national experts as they debate and discuss the individualization of treatment plans for patients with gynecologic cancers (such as surgery, adjuvant therapy, chemotherapy, and maintenance therapy), as well as the role of robotic surgery and genomic analyses. Promising novel chemotherapeutics and targeted agents for gynecologic malignancies currently undergoing clinical trial evaluation will also be highlighted during the program. Finally, participants will have an opportunity to submit their own cases for discussion with a faculty tumor board.
This highly practical and interactive forum will provide a unique opportunity for medical, surgical, and radiation oncologists and other health care professionals to learn from and interact with leading national faculty in order to increase clinical knowledge, apply new data to practice, and ultimately improve patient outcomes.

Target Audience

This educational activity is directed toward medical oncologists and fellows who treat patients with ovarian cancer. Gynecologic oncologists, surgical oncologists, radiation oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of ovarian cancer will be invited to participate.

Learning Objectives

  • Formulate frontline and subsequent therapy for patients based upon patient/disease characteristics including use of surgery and adjuvant therapy
  • Discuss the use of first-line intraperitoneal chemotherapy for eligible patients with ovarian cancer
  • Describe the value of maintenance therapy for appropriate patients with ovarian cancer following first-line chemotherapy
  • Assess treatment options for second-line therapy for recurrent metastatic ovarian cancer based on sensitivity or resistance to prior platinum-based chemotherapy
  • Evaluate data on new agents and approaches in development for ovarian cancer
  • Recommend appropriate patients with ovarian cancer for clinical trial enrollment 

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of PER to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI.
Additionally, PER® is required by ACCME to resolve all COI. We have identified and resolved all COI prior to the start of this activity by using a multi-step process.

Faculty and Staff Disclosures

The following individuals have no relevant financial relationships with commercial interests to disclose: Michael J. Birrer, MD, PhD; Mark A. Morgan, MD, FACOG, FACS; and Russell J. Schilder, MD.
The staff of Physicians’ Education Resource®, LLC: Wendy Ashmen; Dru S. Dace, PhD; Kate Doherty; Ann C. Lichti, CCMEP; and Megan O’Connell.
The following individuals have relevant financial relationships with commercial interests to disclose:
Robert A. Burger, MD, FACOG, FACS – Consultant: Boehringer Ingelheim Pharmaceuticals, Inc, GlaxoSmithKline, and Amgen. Maurie Markman, MD – Consultant: Genentech, Amgen, GlaxoSmithKline, Celgene Corporation, and BIND Therapeutics, Inc. James Tate Thigpen, MD – Consultant: Genentech, Janssen Biotech, Inc, and Boehringer Ingelheim Pharmaceuticals, Inc; Member of Speaker’s Bureau: Genentech, Janssen Biotech, Inc, Boehringer Ingelheim Pharmaceuticals, Inc, and Celgene Corporation.

Off-Label Disclosure and Disclaimer

This CME activity will contain discussions of investigational, unapproved, or off-label use of drugs including but not limited to bevacizumab, ipilimumab, nivolumab, INCB-24360, aflibercept, pazopanib, BIBF 1120, AMG 386, and MPDL3280A. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.


The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

In case of onsite emergency:

Professional Information


Calendar of Events
Filter By